Atara Biotherapeutics Inc. (Nasdaq: ATRA) halted development of PINTA 745 to treat protein energy wasting in patients with end stage renal disease after disappointing results from a Phase 2 clinical trial. The stock price plummeted $12.20 to close at $21.00.
Atara Biotherapeutics halts PINTA 745 development
December 14, 2015 at 18:44 PM EST
